Although borderline changes (BL) suspicious for acute T-cell-mediated rejection represent a diagnostic category, its clinical relevance is questioned leading to heterogeneous therapeutic management. We hypothesized that measuring IL-6 secretion by peripheral blood mononuclear cells identifies patients with ongoing graft damage. We examined the association between secreted IL-6 and the change in estimated glomerular filtration rate at 6 months after the biopsy (DeGFR). We then conducted phenotypic and functional studies on patient and mouse innate immune cells in the blood and the kidney. In a training set, DeGFR was strongly associated with IL-6 levels, showing a clinically meaningful decline of 4.6 AE 1.5 ml/min per increase in log10 IL-6 (P = 0.001). These results were consistent after adjustment and were reproduced in a validation cohort. Phenotyping of peripheral blood cells revealed that the main source of IL-6 was CD14 + inflammatory monocytes. There was a significant correlation between IL-6 secretion and interstitial dendritic cell density in the biopsy. Finally, characterization of mouse kidney dendritic cells revealed that they share features with macrophages and function as effector cells secreting IL-6. In conclusion, measuring IL-6 secreted by peripheral blood cells can be useful in the management of patients with BL in the absence of a concurrent inflammatory condition.
SUMMARY
Although borderline changes (BL) suspicious for acute T-cell-mediated rejection represent a diagnostic category, its clinical relevance is questioned leading to heterogeneous therapeutic management. We hypothesized that measuring IL-6 secretion by peripheral blood mononuclear cells identifies patients with ongoing graft damage. We examined the association between secreted IL-6 and the change in estimated glomerular filtration rate at 6 months after the biopsy (DeGFR). We then conducted phenotypic and functional studies on patient and mouse innate immune cells in the blood and the kidney. In a training set, DeGFR was strongly associated with IL-6 levels, showing a clinically meaningful decline of 4.6 AE 1.5 ml/min per increase in log10 IL-6 (P = 0.001). These results were consistent after adjustment and were reproduced in a validation cohort. Phenotyping of peripheral blood cells revealed that the main source of IL-6 was CD14 + inflammatory monocytes. There was a significant correlation between IL-6 secretion and interstitial dendritic cell density in the biopsy. Finally, characterization of mouse kidney dendritic cells revealed that they share features with macrophages and function as effector cells secreting IL-6. In conclusion, measuring IL-6 secreted by peripheral blood cells can be useful in the management of patients with BL in the absence of a concurrent inflammatory condition.
Introduction
Biopsies with borderline changes suspicious for acute T-cell-mediated rejection (BL) present a challenge for transplant physicians [1] . One of the mandates of the Banff renal working group on T-cell-mediated rejection (TCMR) is to determine whether the BL category should be modified to identify lesions specific for active TCMR [1] . From a clinical management standpoint, the BL category is of undetermined clinical significance [2] . Since 2005, the range of histological lesions that are classified as BL has been broadened and now varies from tubulitis (t) with minor interstitial inflammation (i), scored as t1-3 with i0-1, to mild t with variable i, scored as t1 with i2-3 [3, 4] . More recently, the score of total inflammation in the allograft cortex, including scarred and nonscarred areas (ti score), has been shown to be a better predictor of graft outcomes than the "i" score, but as of yet has not replaced "i" score in the Banff diagnostic scheme [1, [5] [6] [7] . Molecular phenotyping suggests that most cases of BL probably do not represent rejection [8] . However, as molecular and histological studies were performed on different samples (formalin-fixed samples for histological assessment versus frozen samples for molecular assessment), this issue is still not fully resolved [9] .
Although it might prove difficult to identify a tissuespecific lesion for active TCMR, the characterization of other nonhistological signs of immunological activity in patients with BL could potentially be helpful. We have previously shown in different cohorts of kidney recipients that patients with rejection of any kind have systemic activation of the innate immune system, as witnessed by high levels of proinflammatory cytokines, such as IL-6, IL-1b, TNF-a, and MCP-1 (also referred to as CCL2) secreted ex vivo by peripheral blood mononuclear cells (PBMCs) [10] [11] [12] . In a validation set, IL-6 was shown to be the best predictor of acute rejection [10] . More recently, we demonstrated that dendritic cells (DC) cluster with T cells infiltrating the human allograft and observed direct contact between DCs and T cells by electron microscopy [13] . Furthermore, we found that high DC density in kidney allografts was associated with greater T-cell proliferation and with poor outcomes in patients with high total inflammation scores [13] . Whether or not there is a link between peripheral activation of the innate immune cells in the blood and those within the kidney is still not well defined.
In this study, we tested and validated whether measuring PBMC IL-6 secretion was prognostically useful to predict decline in graft function in patients once BL is confirmed by histology. We further characterized the subset of PBMCs responsible for IL-6 secretion, and then explored the association of IL-6 with DC and macrophage density in allograft biopsies with BL. Finally, we characterized mouse kidney DCs to examine their phenotypes and functions, in particular, their production of IL-6.
Materials and methods

Study design and population
This was an observational study with prospective collection of biological samples and clinical data in a testing set and an independent validation set. The testing set was obtained from a single-center cohort of 105 participants enrolled between January 2012 and June 2015. Patients were invited either to provide blood and urine sample at the time of an indication graft biopsy and follow-up samples at 3 months (n = 55) or to participate in a longitudinal sample collection at several time points post-transplant (n = 50). Of these, fifty-nine patients provided biological samples at the time of an indication biopsy (Fig. 1 ). Among them, 32 patients diagnosed with BL were included [7] using the threshold of t1i0, in line with the current classification. We excluded patients with complete criteria for antibodymediated rejection (ABMR), infection or glomerulonephritis by light and electron microscopy. Twenty-six patients had BL without any sign of ABMR, whereas six had nondiagnostic components of ABMR. The validation set was assembled from patients enrolled at the Brigham and Women's Hospital and Quebec University Health Center (n = 15). No patients were lost to follow-up. A smaller independent study cohort of nine patients with BL was used for phenotypic characterization of cells in the biopsy [13] . The study was approved by the institutional ethics committees and is consistent with the Principles of the Declaration of Istanbul.
Pathologic classification
The biopsies were graded by the local attending pathologists according to the Banff 1997 criteria, which were updated in 2003, 2008, and 2013 [1,3,14] . Pathologists were blinded to the results of the cytokine measurements.
Definition of exposures and outcomes
The primary outcome was the change in estimated glomerular filtration rate (eGFR) at 6 months compared with eGFR at the time of the biopsy. DeGFR was calculated as eGFR 6 month À eGFR biopsy . Exposure was defined as the IL-6 levels at the time of the biopsy. Because IL-6 levels were not normally distributed, log10 transformation was used.
Cell isolation and cytokine assay PBMC samples were isolated, frozen, stored, and thawed as described previously [10] , then incubated for 24 h without stimulation in X-vivo 15 serum-free medium (Lonza, Walkersville, MD, USA) in triplicates in a 96-well plate, at a concentration of 5 9 10 6 cells/ml. IL-6 in cell supernatants was measured using a single ELISA (BioLegend, San Diego, CA, USA). In a second experiment, MCP-1, IL-1b, TNF-a, and INF-c were measured using a multiplex ELISA (Aushon Biosystems, Billerica, MA, USA).
Flow cytometry of human PBMCs
Reconstituted cells were incubated and then stained as detailed in the Appendix S1.
Characterization of mouse DCs
Dendritic cell features and function were examined as detailed in the Appendix S1.
Statistical analyses
The association between DeGFR and IL-6 was assessed using Spearman correlation test and by linear regression models. The association between the primary outcome and MCP-1, IL-1b, and TNF-a was performed using multivariable linear regression models. Proportions of positive cell subsets were compared using Chi-square and Fisher's exact tests. Percentages of IL-6-positive versus IL-6-negative cells were compared by paired t-tests for each subset. Mice data were compared using t-test. Statistical analyses were performed using STATA version 11.0 (StataCorp, College Station, TX, USA) and graphs using SPSS STATISTICS v.23 (IBM, Armonk, NY, USA) and GRAPHPAD PRISM 5 (GraphPad Software, San Diego, CA, USA). All tests were two tailed, and a P < 0.05 was considered statistically significant.
Results
Training cohort and graft dysfunction at 6-month postbiopsy
Baseline demographic, clinical, and histological characteristics of the 32 patients studied in the training cohort are displayed in Training cohort (n = 32) 26 Pure BL 6 BL with non Dx ABMR 2 cg0 g1 ptc0 C4d0 1 cg0 g2 ptc0 C4d0 1 cg1 g0 ptc0 C4d0 1 cg1 g1 ptc0 C4d0 1 cg2 g0 ptc0 C4d0 had an increase in serum creatinine level above 25% of their baseline value and received solumedrol (total dose 600 mg) and one patient who had a low mycophenolate mofetil dose at the time of diagnosis was increased from 1250 to 1750 mg daily. In all cases, urinary tract infection was ruled out by urine culture and SV40 staining was negative for polyomavirus nephropathy.
There was no graft loss during the follow-up period. The eGFR at 6 months compared with baseline (DeGFR) varied substantially between patients, from À12 to +23 ml/min (Fig. 2a) . Seventeen patients (53%) suffered from a decline in eGFR. We conducted simple linear regression analyses to examine potential relationships between baseline characteristics (listed in Table 1 ) and DeGFR. The only finding was a nearly significant association with tacrolimus through level (P = 0.069). There was no evidence of a correlation between DeGFR and any other clinical or histological characteristic, in particular, neither with "t", "i" nor with "ti" scores (P = 0.86, P = 0.63, and P = 0.54, respectively, Table S1 ).
Association between DeGFR and IL-6 levels in cell culture supernatants PBMCs collected at biopsy were cultured under resting conditions, and IL-6 levels were measured in supernatants. Because of the skewed distribution of the cytokine levels, we used log10 IL-6 values to examine their association with DeGFR. There was a significant raw negative correlation between DeGFR and IL-6 levels (r = À0.55, P = 0.001; Fig. 2b ). Consistent with these findings, the unadjusted linear regression model showed a significant relationship, in which, each increase in one log10 IL-6 was associated with a clinically meaningful decline in eGFR of 4.6 AE 1.5 ml/min (P = 0.001; Fig. 2c ). This association was robust following progressive adjustment for initial eGFR at biopsy, antirejection treatment, and time post-transplant ( Fig. 2c and Table S2 ). We next sought to determine if there was an association between IL-6 levels and t, i, t + i, or ti scores and found no such evidence. In all, these findings indicate a strong link between a proinflammatory IL-6 state in the circulation and a decline in graft function at 6 months. They further suggest that IL-6 levels provide different, additional clinical information to the histological t and i scores.
To better assess the cellular activation in the clinical setting, we next compared IL-6 levels of BL patients to those of the non-BL patients and classified them under their clinical diagnosis and also under the following categories: overt rejection (TCMR, ABMR, or mixed rejection), infection, and noninflamed biopsies (acute tubular necrosis and normal biopsies; Fig. S1 ). Similar to our previous report [10] , we found that patients with BL had a range of IL-6 levels encompassing both inflamed and noninflamed conditions (Fig. S1a,b) . The mean (AESEM) Log10-IL6 was 2.4AE0.2 vs. 2.8AE0.4 for pure BL and non-diagnostic ABMR, respectively (p=0.30). These observations were consistent with the hypothesis that, whereas some BL have ongoing immune activation, others are immunologically quiescent.
Association between DeGFR and other proinflammatory cytokines or IFN-c
Because we previously found an association, albeit of lower magnitude, between acute rejection and other cytokines, we examined these cytokines in the cell culture. We found a significant, but less robust, association between DeGFR and each of MCP-1 and IL-1b but not with TNF-a (Table S3) . Because TCMR has been classically associated with IFNc, we also quantified this cytokine in the supernatant. We found no signal for an association between IFNc levels and DeGFR, neither by simple linear regression nor by multivariable linear regression (P = 0.52 and P = 0.56, respectively; data not shown). Taken together, these results suggest that the signal observed with IL-6 is not seen or only detected to a lower degree with other proinflammatory markers. 
Stability of IL-6 production over time
Three-month follow-up blood samples were available for 19 patients. To determine the variability in IL-6 production over time, we studied these samples under the same conditions. During this time, all the patients kept a stable immunosuppression maintenance regimen and did not suffer from serious concurrent medical conditions, except two patients who had acute pyelonephritis and one who developed BK viremia. These diagnoses were made after the biopsy. These three patients were analyzed separately. The remaining patients were compared with six controls, who underwent protocol biopsies showing no significant allograft inflammation (t0i0) and from whom blood was available at the time of the biopsy and 3 months thereafter. As displayed in Fig. S2a , IL-6 levels in controls were fairly stable over time, with a mean (SD) change of À0.11 (0.40) log10 value between the 3-month and baseline time points. Patients with BL had a large range of between-patient variation in IL-6 levels (from À1.48 to 1.78 log10 value) although the within-patient variations were minimal (Fig. S2b) . The three patients with infection at the 3-month time point had a marked increase in IL-6 levels [mean (SE) 1.76 (0.42) log10 value from baseline, P = 0.002; Fig. S2c ]. In all, these data indicate that the secretion of IL-6 by PBMCs ex vivo was relatively stable over time, except for patients who developed an active infection.
External validation
To validate these observations, we assembled an independent, multicenter cohort of 15 patients with BL on indication biopsies. First, the data from this set confirmed that IL-6 in patients with BL varies widely, from 1.9 to 4.1 log values (Fig. 2d) . Second, we observed a similar association between DeGFR and log IL-6 and found that this relationship was of similar magnitude both in the unadjusted and adjusted models (À6.8 AE 2.1 and À6.0 AE 1.8 ml/min per logIL-6 for unadjusted and fully adjusted models, respectively, P = 0.007 and P = 0.007, respectively; Fig. 2d ,e and Table S4 ).
Phenotype of IL-6-secreting cells
We next sought to examine the precise cell subset responsible for IL-6 secretion. We first coupled intracellular IL-6 staining to surface staining for T (CD3 + ) cells, B (CD19 + ) cells, monocytes (CD14 + ), and DCs (CD14
À
CD11c
+ ) [15] . Whereas only a minimal fraction of T and B cells expressed IL-6, a large proportion of monocytes and DCs expressed the cytokine (Fig. 3a,b) . To better characterize the innate cell subset responsible for IL-6 secretion, we used a multicolor panel and found that compared with IL-6-negative cells, IL-6-positive cells were predominantly CD14 + CD16 À CCR2 + HLA-DR + CD86 + CD11c + , which can be termed inflammatory monocytes (Fig. 3c,d) . Collectively, our data indicate that these cells are the main source of IL-6 in the peripheral blood of kidney recipients with BL.
To further study the relationship between IL-6 secretion of PBMC and innate immune cells within the graft, we analyzed an independent set of patients with BL and investigated the correlation between IL-6 secretion by PBMCs and the frequency of interstitial monocytes/ macrophages (CD68) and DCs (CD209) in the biopsy (n = 9). Interestingly, we found a strong correlation between IL-6 levels and the frequency of DCs (r = 0.71, P = 0.03) but not with macrophages (r = 0.35, P = 0.36; data not shown).
Phenotypic and functional characterization of kidney DCs
This led us to explore the potential link between IL-6-secreting monocytes in the blood with BL and innate immune cells within the kidney. Monocytes are composed of a heterogeneous population of circulating blood cells belonging to the mononuclear phagocyte system [16] . Once migrated in the tissue, they differentiate into effector cells [15] . Although the nomenclature for these cells is still controversial, they can be termed monocytederived macrophages or DCs [17, 18] . Here, we used the C57Bl/6 and CX3CR1 GFP+ mice and examined the morphology of these cells and their secretion of IL-6. First, we observed that DCs' resident in the kidney was smaller than splenic DCs and as demonstrated previously [19] , had a higher percentage of CX3CR1 + F4/80 + cells, suggesting phenotypic features of macrophages (Fig. 4a,b) . Second, kidney DCs demonstrated a higher secretion capacity for IL-6, a lower capacity for proliferation of CFSE-labeled CD8 + and CD4 + T cells, and a lower production of IL-2 in mixed lymphocyte reaction (MLR) supernatants, compared with splenic DCs (Fig. 4c-e) . These results were confirmed in an antigen-specific model in which kidney and splenic DCs were incubated with OVA-1 peptide for 3 h and cocultured with CD8 + T cells from OT-I mice (OVA-specific TCR transgenic mice of C57Bl/6 background in which OT-I CD8 + T cells recognize OVA-I peptides) (data not shown). In all, these results indicate that kidney DCs share features with macrophages and function as effector cells secreting IL-6.
Discussion
In this study, we present a cohort of patients with BL for whom we performed a detailed examination of the PBMC inflammatory profile at the time of the biopsy. We analyzed the correlation between IL-6 and progressive graft dysfunction at 6 months. The first relevant finding is that DeGFR of these patients varied substantially within this period. Second, there was a strong and clinically relevant association between IL-6 secretion by PBMCs at the time of biopsy and decline in graft function at 6 months. We validated this finding in an external cohort. Although the relevance of the BL category is being questioned, our findings indicate that a marker of PBMC activation, such as IL-6, may provide the missing information to identify patients with ongoing tissue damage among this population. The cells that secreted IL-6 in highest proportion were the classic-type monocytes and DCs [20] .
The presence of activated monocytes in the blood of rejectors is reminiscent of the role of these cells following infection, during which there is an increase in circulating immature monocytes, emerging from the bone marrow in a CCR2-dependent fashion [21] . Expression of CCR2 on CD14 + CD16 À circulating monocytes leads to higher migration responsiveness for MCP-1/CCL2 at injured sites, specifically on the endothelial cells [16, 21, 22] . These observations extend recent findings that we reported on the relationship between high intragraft DC density, high histological inflammation scores, and poor graft prognosis [13] . We observed that, whereas DCs were of donor origin early post-transplant, the proportion progressively decline during the firstyear post-transplant [13] . Our findings are also consistent with recent gene expression profile microarray data from renal biopsies of patients with BL. Hruba et al. [23] observed and validated that donor age and expression of the macrophage receptor C-type lectin domain family 5 member A (CLEC5A) were independent factors of progression in patients with BL. CLEC5A expression is prominent on recruited blood monocytes that enter the tissue upon inflammation and differentiate into proinflammatory cells [24] . Human CLEC5A+ cells express CD14 and CD11c surface markers and secrete proinflammatory cytokines such as TNF-a and IL-6 [24, 25] . These data support the hypothesis that, during BL, recruited blood monocytes differentiate intragraft into inflammatory innate immune cells, which is in continuum with the observations that we made here in the peripheral blood.
It is tempting to speculate that the IL-6 signal observed here is not only a marker of disease activity, but could be a potential therapeutic target. Anti-IL-6 is currently under investigation to prevent damage in inflamed allografts and has been shown to be potentially useful to treat chronic ABMR [26, 27] . In an elegant study, Oberbarnscheidt et al. [28] demonstrated that recognition of allogeneic grafts can elicit differentiation of monocytes into mature DCs, which, in turn, stimulate T-cell proliferation, underscoring the role of monocytes in initiating rejection. It is conceivable that, under standard immunosuppression, this mechanism leads to a smoldering rejection, which does not produce a fullblown TCMR, but rather BL changes leading to interstitial fibrosis and tubular atrophy. However, the data presented here cannot confirm the causative role of IL-6 in the pathogenesis of rejection.
There are some limitations to this study. First, the sample size is small but comparable to recent studies examining gene expression profile in patients with BL [23] . Furthermore, the magnitude of the association observed between DeGFR and IL-6 levels is clinically relevant. Second, the follow-up period is relatively short. Perhaps the best endpoint to conclusively demonstrate the impact of peripheral inflammation in patients with BL will be a combination of decline in graft function and progressive chronic allograft damage over time. It is plausible that a sizeable proportion of BL cases will not lead to TCMR but contribute to long-term graft damage. The observations reported in this article suggest that secretion of IL-6 by PBMCs may be a marker of ongoing tissue damage that could indicate, among patients with BL, who would benefit from increased surveillance and perhaps antirejection treatment. The mechanistic data on kidney DCs further suggest that they might originate from an IL-6-secreting blood monocyte precursor, providing the impetus to determine the role of these cells and anti-IL-6 treatment in patients with BL. Figure S1 . Comparison of IL-6 levels between subcategories. Figure S2 . Variation in IL-6 levels over time. Table S1 . Simple linear regression models for the prediction of DeGFR by t, i and ti scores. Table S2 . Detailed linear regression models for the prediction of DeGFR by log10 IL-6. Table S3 . Simple linear regression models for the prediction of DeGFR by MCP-1, IL-1b and TNF-a levels in the culture supernatants. Table S4 . Detailed linear regression models for the prediction of DeGFR by log10 IL-6 in the validation cohort.
Appendix S1. Complete methods.
